Antihypertensive Dose Converter

Evidence-based same-class dose equivalents (ACE-I, ARB, CCB only)

mg

0 mg (approx)

Clinical Disclaimer:

These conversions are approximate therapeutic equivalents for hypertension treatment based on published clinical trials and guidelines. Individual patient response varies. Always monitor blood pressure closely when switching agents and adjust doses based on clinical response.

Evidence-Based Dose Equivalents

ACE Inhibitors

Drug Approx. Equivalent Dose Evidence Source
Lisinopril 10 mg daily UCSF Hospital Handbook
Enalapril 10 mg daily UCSF Hospital Handbook
Ramipril 5 mg daily PARADISE-MI Trial
Benazepril 10 mg daily GlobalRPH

Angiotensin Receptor Blockers (ARBs)

Drug Approx. Equivalent Dose Evidence Source
Losartan 50 mg daily Pharmacist's Letter 2018
Valsartan 80 mg daily VA Study, Pharmacist's Letter
Irbesartan 150 mg daily VA Study, Pharmacist's Letter
Olmesartan 20 mg daily Pharmacist's Letter 2018
Telmisartan 40 mg daily Pharmacist's Letter 2018

Dihydropyridine Calcium Channel Blockers

Drug Approx. Equivalent Dose Evidence Source
Amlodipine 5 mg daily Clinical trials
Nifedipine ER 30 mg daily Conversion studies

Note: Non-dihydropyridine CCBs (diltiazem, verapamil) have different mechanisms and are not included in conversions.

Clinical Pearls

  • Same-class conversions only: This tool restricts conversions to medications within the same class because different classes (ACE-I vs ARB vs CCB) work through different mechanisms and have no established dose equivalency.
  • Individual variation: Blood pressure response to antihypertensives varies significantly based on genetics, volume status, and comorbidities. Always titrate based on clinical response.
  • ARB potency differences: Irbesartan and telmisartan are more potent than losartan. Clinical trials show irbesartan 150 mg provides greater BP reduction than losartan 100 mg.
  • Monitor after switching: Check BP within 2-4 weeks after medication changes. Some patients may require dose adjustments.